ALB and chronic kidney disease: The fully specified model in patients with CKD stage G3 found the following 2 variables to be significant predictors of monthly costs: (i) serum bicarbonate (1 mEq/l increase associated with a 7.0% decrease in monthly costs) and (ii) serum albumin (1 g/dl increase associated with a 55.5% decrease in monthly costs).